Transitioning your practice to VAXELIS now may lead to improved efficiencies that may impact your patients, staff, and office1-8

With 2-3 fewer shots in the infant vaccination series compared to pentavalents (+ hep B or Hib vaccine), VAXELIS may help simplify some aspects of vaccine-related tasks1-3

Patients

Less of a shot burden for baby and parents and the potential for increased compliance with the infant vaccination schedule1-5,8

Read more

Staff

Reduction in tasks associated with billing, ordering, and vaccine preparation—which may help save time and improve efficiencies with administrative responsibilities1-7

Read more

Office

No reconstitution and fewer shots result in fewer needles needed across the infant vaccine series, and less needles to dispose of.1-3

Read more
View transition detail PDF

Patients

Fewer shots for baby

Research has shown that the number of shots children receive in a single visit is a key parental concern. With VAXELIS, you may reduce the shot burden at the 2-, 4-, and 6-month visits.1-3,8

May Improve Compliance

Research has shown that some parents are concerned about the number of injections their children receive during the first 2 years of life, which may lead to reduced vaccination compliance. With fewer shots needed with VAXELIS, this may help improve vaccination compliance in the infant series.1-3,5,8

Staff

Fewer Shots Administered

The number of injections has a direct impact on the time it takes to perform vaccine-related tasks. With fewer shots across the infant vaccine series, incorporating VAXELIS into your practice may help improve efficiency and reduce administrative tasks.1-7

Billing and coding

1 NDC with VAXELIS versus 2 NDCs with a pentavalent + monovalent may help reduce tasks associated with billing for vaccines.1,2

Ready-to-Use Formulation

VAXELIS comes in ready-to-use prefilled syringes —unlike Pentacel®, which requires reconstitution—a fully liquid vaccine formulation like VAXELIS may reduce vaccine prep time.1,4,6

View the steps side-by-side on the comparison checklist

Ordering & Inventory Management

Routine tasks like ordering and inventory management can be complicated. VAXELIS is a hexavalent that requires 2-3 fewer shots, so it may help reduce some of the need for additional hep B or Hib vaccines (as with pentavalents), meaning fewer vaccines to order and manage.1-3,5

Office

Fewer Needles

Because VAXELIS requires fewer shots and does not need to be reconstituted, it can reduce the quantities of needles required.1-3

More Refrigerator Space

With VAXELIS, you may be able to keep fewer vaccine doses in stock. You may also be able to save room in the refrigerator due to packaging differences compared to pentavalents (+ hep B or Hib vaccine).5,9-12

Less Needle Waste

Incorporating VAXELIS into your practice will result in 2-3 fewer shots per patient, so for every 100 infant patients who are administered VAXELIS, there may be between 200-300 fewer needles to dispose of.1,2

May Reduce Administration Errors

By reducing the number of injections that must be prepped, reconstituted, and administered for each patient, there may be a reduction in errors associated with administration.3,5,6

Order VAXELIS now

Order directly at: VaccineShop.com

For a list of authorized distributors: VaxelisContract.com

References: 1. Pentacel. Prescribing Information. NDC No. 49281-511-05. Sanofi Pasteur; 2022. 2. PEDIARIX. Prescribing Information. GlaxoSmithKIine; 2022. 3. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2023. Accessed September 19, 2023. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf 4. Pellissier JM, Coplan PM, Jackson LA, May JE. The effect of additional shots on the vaccine administration process: results of a time-motion study in 2 settings. Am J Manag Care. 2000;6(9):1038-1044 5. Centers for Disease Control and Prevention. General best practice guidelines for immunization. Accessed September 19, 2023. https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html 6. De Coster I, Fournie X, Faure C, et al. Assessment of preparation time with fully-liquid versus non-fully liquid paediatric hexavalent vaccines. A time and motion study. Vaccine. 2015;33(32):3976 -3982. doi:10.1016/j.vaccine.2015.06.030 7. Ciarametaro M, Bradshaw SE, Guiglotto J, Hahn B, Meier G. Hidden efficiencies: making completion of the pediatric vaccine schedule more efficient for physicians. Medicine (Baltimore). 2015;94(4):e357. doi:10.1097/MD.0000000000000357 8. Kennedy A, Lavail K, Nowak G, Basket M, Landry S. Confidence about vaccines in the United States: understanding parents’ perceptions. Health Aff (Millwood). 2011 Jun;30(6):1151-9. doi: 10.1377/hlthaff.2011.0396 9. Sanofi. Product Catalog, Vaccines & Biologics, VAXELIS, 1 carton of 10 prefilled syringes. VaccineShoppe.com. Accessed September 19, 2023. https://www.vaccineshoppe.com/us/vsh/en/USD/Product-Catalog/Vaccines-%26-biologics/Vaxelis%E2%84%A2/p/243-15 10. Sanofi. Product Catalog, Vaccines & Biologics, VAXELIS, 1 carton 10 vials. VaccineShoppe.com. Accessed September 19, 2023. https://www.vaccineshoppe.com/us/vsh/en/USD/Product-Catalog/Vaccines-%26-biologics/Vaxelis%E2%84%A2/p/243-10 11. Vaccine Shoppe. Vaccine & Biologics. Pentacel. Accessed September 19, 2023. https-//www.vaccineshoppe.com/us/vsh/en/USD/Product-Catalog/Vaccines-%26-biologics/Pentacel%C2%AE/p/511-05 12. GlaxoSmithKline. PEDIARIX pre-filled syringe ordering information. Accessed September 19, 2023. https://www.gskdirect.com/gsk/en/USD/RootCategory/Vaccines%28non-flu%29/PEDIARIX-PFS1DOSE-0-5ML-NO-NDL-10S-LM/p/58160081152?pro-from=product-list

What is VAXELIS?

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

Important Safety Information

  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
  • Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
  • Carefully consider benefits and risks before administering VAXELIS to persons with a history of: fever ≥40.5°C (≥105°F), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.
  • If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant’s medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.
  • Vaccination with VAXELIS may not protect all individuals.
  • The solicited adverse reactions 0-5 days following any dose were irritability (≥55%), crying (≥45%), injection site pain (≥44%), somnolence (≥40%), injection site erythema (≥25%), decreased appetite (≥23%), fever ≥38.0°C (≥19%), injection site swelling (≥18%), and vomiting (≥9%).
  • The 3-dose immunization series consists of a 0.5 mL intramuscular injection, administered at 2, 4, and 6 months of age.
  • A 3-dose series of VAXELIS does not constitute a primary immunization series against pertussis; an additional dose of pertussis-containing vaccine is needed to complete the primary series.

Before administering VAXELIS, please read the accompanying Prescribing Information. The Patient Information also is available.

What is VAXELIS®? (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus,

VAXELIS is a vaccine indicated for active immunization to prevent diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive disease due to Haemophilus influenzae type b (Hib). VAXELIS is approved for use as a 3-dose series in children 6 weeks through 4 years of age (prior to the 5th birthday).

Important Safety Information for VAXELIS® (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine)

  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.
  • Do not administer VAXELIS to anyone with a history of progressive neurologic disorder until a treatment regimen has been established and the condition has stabilized.
  • Carefully consider benefits and risks before administering VAXELIS to persons with a history of: fever ≥40.5°C (≥105°F), hypotonic-hyporesponsive episode (HHE), or persistent, inconsolable crying lasting ≥3 hours within 48 hours after a previous pertussis-containing vaccine; and/or seizures within 3 days after a previous pertussis-containing vaccine.
  • If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS.
  • Apnea following intramuscular vaccination has been observed in some infants born prematurely. Consider the individual infant’s medical status and potential benefits and possible risks of intramuscular vaccination in deciding when to administer VAXELIS to an infant born prematurely.
  • Vaccination with VAXELIS may not protect all individuals.
  • The solicited adverse reactions 0-5 days following any dose were irritability (≥55%), crying (≥45%), injection site pain (≥44%), somnolence (≥40%), injection site erythema (≥25%), decreased appetite (≥23%), fever ≥38.0°C (≥19%), injection site swelling (≥18%), and vomiting (≥9%).
  • The 3-dose immunization series consists of a 0.5 mL intramuscular injection, administered at 2, 4, and 6 months of age.
  • A 3-dose series of VAXELIS does not constitute a primary immunization series against pertussis; an additional dose of pertussis-containing vaccine is needed to complete the primary series.

Before administering VAXELIS, please read the accompanying Prescribing Information. The Patient Information also is available.

  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of
  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine.
  • Do not administer VAXELIS to anyone with a history of encephalopathy within 7 days of a pertussis-containing vaccine with no other identifiable cause.